Compare VANI & GRABW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VANI | GRABW |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | 11267 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.0M | N/A |
| IPO Year | 2014 | N/A |
| Metric | VANI | GRABW |
|---|---|---|
| Price | $1.22 | $0.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | ★ 184.1K | 28.0K |
| Earning Date | 05-14-2026 | 02-21-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,000,000.00 | ★ $2,686,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 21.65 |
| 52 Week Low | $0.92 | $0.04 |
| 52 Week High | $1.92 | $0.58 |
| Indicator | VANI | GRABW |
|---|---|---|
| Relative Strength Index (RSI) | 53.12 | 32.10 |
| Support Level | $1.23 | $0.04 |
| Resistance Level | $1.26 | $0.11 |
| Average True Range (ATR) | 0.06 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 80.00 | 17.36 |
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
Founded in 2012, Grab provides ride-sharing services, food and grocery delivery, and financial services (payments, consumer loans, and enterprise offerings) in eight Southeast-Asian countries through its mobile platform. The company partners with merchants and riders, connecting them with consumers while charging commission to both sides. Grab has a leading market share in and derives 89% of its revenue from its core businesses, ride-sharing and food delivery. Singapore, Indonesia, and Malaysia contributed more than 70% of revenue in 2024. Grab's main competitors in Southeast Asia are Line Man and Goto. Its financial services business is still in its nascent stage and provides minimal revenue currently. The company now also generates advertising revenue.